Welcome to our dedicated page for Grail SEC filings (Ticker: GRAL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Biotech disclosures can feel like a second language—especially when GRAIL’s 10-K spells out hundreds of pages of clinical trial statistics, cash-burn tables, and regulatory risk factors tied to its Galleri multi-cancer early detection test. Finding the pivotal trial read-outs or decoding executive stock moves before major data releases shouldn’t require a medical degree.
Stock Titan’s platform turns that challenge into a two-minute task. Our AI-powered summaries convert dense narratives into plain English, so understanding GRAIL SEC documents with AI is as direct as reading a headline. Receive real-time alerts the moment a GRAIL Form 4 insider transactions real-time notice hits EDGAR, review a distilled GRAIL quarterly earnings report 10-Q filing, or open a GRAIL 8-K material events explained brief that pinpoints new clinical milestones.
Use the filings that matter most:
- GRAIL annual report 10-K simplified – track R&D outlays, patent positions, and Galleri commercialization strategy.
- 10-Q trends – rapid GRAIL earnings report filing analysis for cash-runway checks.
- GRAIL insider trading Form 4 transactions – uncover buying or selling before clinical data drops.
- GRAIL proxy statement executive compensation – see how trial success metrics drive pay packages.
Whether you’re monitoring GRAIL executive stock transactions Form 4 or verifying a new partnership disclosed in an 8-K, our comprehensive, continuously updated library ensures GRAIL SEC filings explained simply. Skip the jargon, focus on the insight, and make faster, better-informed decisions about this precision-oncology pioneer.
On June 26, 2025, Quanterix Corporation (QTRX) filed an 8-K to announce logistics for its 2025 Annual Meeting of Stockholders. The meeting will be held virtually on September 23, 2025 at 9:00 a.m. ET. Because the meeting date falls more than 30 days after the 2024 meeting anniversary, the company has reset key shareholder deadlines:
- Rule 14a-8 proposals must be received by the corporate secretary by July 11, 2025.
- Bylaw-based business or director nominations (outside Rule 14a-8) also require written notice by July 11, 2025.
- Universal proxy notification (Rule 14a-19) is due by July 25, 2025.
No financial results, strategic transactions or operational updates were disclosed. The filing is procedural, ensuring compliance with SEC rules and providing investors sufficient time to submit proposals or nominations.
Form 144 Overview: GRAIL, Inc. (symbol GRAL) has filed a Form 144 indicating that an affiliate plans to sell 9,692 common shares on or about 06/30/2025 through Morgan Stanley Smith Barney LLC.
Key transaction details
- Seller: Joshua J. Ofman (address provided in the filing).
- Securities: Common stock obtained as restricted stock units (RSUs) on 04/30/2025.
- Shares to be sold: 9,692 (aggregate market value $468,995.88).
- Total shares outstanding: 35,973,494, so the proposed sale equals roughly 0.03 % of outstanding shares.
- Exchange: NASDAQ.
Recent insider activity: The filing discloses two prior sales by the same individual during the past three months: 48,213 shares on 05/02/2025 for $1,635,867.09 and 9,692 shares on 06/12/2025 for $410,019.09, some of which were executed under a Rule 10b5-1 trading plan.
Implications for investors: While the absolute dollar amount (~$469k) is modest relative to GRAIL’s total market capitalization implied by the shares outstanding, the notice continues a pattern of insider selling totaling 57,905 shares (~$2.0 million) in the last quarter. Investors often monitor such activity for sentiment cues, although Form 144 filings do not necessarily signal negative fundamentals and may reflect routine diversification or tax-planning.
FAQ
What is the current stock price of Grail (GRAL)?
What is the market cap of Grail (GRAL)?
What is the primary focus of GRAIL Inc.?
How does the Galleri test work?
What technologies does GRAIL use in its diagnostic process?
How is GRAIL positioned within the healthcare industry?
What role do clinical trials play at GRAIL?
How does GRAIL support precision oncology?
What differentiates GRAIL from other diagnostic companies?
What is the significance of the targeted methylation-based platform?
